Clark crosses pond to lead C&W health

Share this article:
Cohn & Wolfe has moved London practice head Jeremy Clark to New York, where he will serve as global healthcare practice leader in September.

Clark takes over from Jennifer Gottlieb, who left the firm to join bicoastal boutique WeissCom Partners in May (as reported in the June issue of MM&M). Anita Bose will serve as deputy director of the healthcare practice.

Clark will report to president and CEO Donna Imperato on global business and to New York president and general manager Michael O'Brien on US accounts. Cohn & Wolfe pharma clients include Pfizer, Aventis, Merck and Endo. Global healthcare accounts include Pfizer's Lyrica.
“Jeremy has been instrumental in growing both the London and European healthcare practices and leading global accounts over the last few years,” said Imperato in a statement. “He is highly skilled and intelligent.”

Imperato and O'Brien did not respond to MM&M inquiries on the reshuffle.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...